Pharmaceuticals Archives

Novartis Fabhalta: Oral Monotherapy for adult patients with PNH

Novartis Fabhalta (iptacopan) receives positive CHMP opinion as first oral monotherapy for adult patients with paroxysmal nocturnal hemoglobinuria (PNH) Novartis has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting a marketing authorization for Fabhalta® (iptacopan) for the treatment […]

Novartis Fabhalta: Oral Monotherapy for adult patients with PNH Read More »

European Commission Approves Pfizer’s PREVENAR 20

Pharmaceuticals / oliviamoss

Pfizer Inc. has announced that the European Commission (EC) has granted marketing authorization for the company’s 20-valent pneumococcal conjugate vaccine, marketed in the European Union under the brand name PREVENAR 20®, for active immunization for the prevention of invasive disease, pneumonia and acute otitis media caused by Streptococcus pneumoniae in infants, children and adolescents from

European Commission Approves Pfizer’s PREVENAR 20 Read More »

Merck Completes Acquisition of Harpoon Therapeutics, Inc.

Pharmaceuticals / oliviamoss

Merck , known as MSD outside of the United States and Canada, has announced the completion of the acquisition of Harpoon Therapeutics, Inc.. Harpoon is now a wholly-owned subsidiary of Merck, and Harpoon’s common stock will no longer be publicly traded or listed on the Nasdaq Stock Market. “We continue to augment and diversify our

Merck Completes Acquisition of Harpoon Therapeutics, Inc. Read More »

Novartis presents new data on safety and efficacy of Zolgensma

Pharmaceuticals / oliviamoss

Novartis presents new data on safety and efficacy of Zolgensma, including maintained and improved motor milestones in older and heavier children with SMA Novartis has presented new data that continue to support the clinical benefits of Zolgensma (onasemnogene abeparvovec), the only one-time gene therapy for the treatment of spinal muscular atrophy (SMA). Final data from

Novartis presents new data on safety and efficacy of Zolgensma Read More »

Pfizer’s GLP-1-RA Program: Obesity and Type 2 Diabetes Update

Pharmaceuticals / oliviamoss

Pfizer Provides Update on GLP-1-RA Clinical Development Program for Adults with Obesity and Type 2 Diabetes Mellitus Pfizer Inc. has announced its decision to continue to progress one oral late-stage glucagon-like peptide-1 receptor agonist (GLP-1-RA) candidate toward further clinical development for the potential treatment of adults with obesity and Type 2 diabetes mellitus (T2DM). Moving

Pfizer’s GLP-1-RA Program: Obesity and Type 2 Diabetes Update Read More »